(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037812 A1

(51) International Patent Classification[7]: C07D 307/68, A61K 31/341, A61P 29/00

(21) International Application Number: PCT/GB2004/004392

(22) International Filing Date: 15 October 2004 (15.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0324269.0	16 October 2003 (16.10.2003)	GB
60/512,200	20 October 2003 (20.10.2003)	US

(71) Applicant *(for all designated States except US)*: **PHARMAGENE LABORATORIES LIMITED** [GB/GB]; 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CLARK, David, Edward** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow ESSEX CM19 5TR (GB). **HARRIS, Neil, Victor** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **FENTON, Garry** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **HYND, George** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **STUTTLE, Keith, Alfred, James** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **SUTTON, Jonathan, Mark** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **OXFORD, Alexander, William** [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **DAVIS, Richard, Jon** [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **COLEMAN, Robert, Alexander** [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **CLARK, Kenneth, Lyle** [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,*

[Continued on next page]

(54) Title: FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS



(I)



(II)



(III)

(57) Abstract: A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R^2 and R^5 is: (i) H or an optionally substituted C_{1-4} alkyl group; or (ii)an optionally substituted C_{5-7} aryl; and the other of R^2 and R^5 is the other group; m and n can be 0 or 1, and m + n = 1 or 2 R^N is H or optionally substituted C_{1-4} alkyl R^3 is either: (i) carboxy; (ii) a group of formula: (II); (iii) a group of formula: (III); wherein R is optionally substituted C_{1-7} alkyl, C_{5-20} aryl, or $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from optionally substituted C_{1-4} alkyl; or (iv) tetrazol-5-yl.

WO 2005/037812 A1

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.